Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2014-10-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14740338.2014.955848PMID 25244502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015influential reference
• Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.

  2014cited by this paper
• Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.

  2014cited by this paper
• US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

  2014cited by this paper
• Genetic and phenotypic diversity in breast tumor metastases.

  2014cited by this paper
• Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.

  2014cited by this paper
• Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

  2014cited by this paper
• Taxonomy of breast cancer based on normal cell phenotype predicts outcome.

  2014cited by this paper
• Breast-conserving therapy for triple-negative breast cancer.

  2014cited by this paper
• Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.

  2014cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

  2014cited by this paper
• Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis

  2014cited by this paper
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  2013cited by this paper
• Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

  2013cited by this paper
• Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

  2013cited by this paper
• Impact of Body Mass Index on Prognostically Relevant Breast Cancer Tumor Characteristics

  2013cited by this paper
• Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

  2013cited by this paper
• Trastuzumab-related cardiotoxicity among older patients with breast cancer.

  2013cited by this paper
• Preventing breast and ovarian cancers in high‐risk BRCA1 and BRCA2 mutation carriers

  2013cited by this paper
• The impact of comorbidity on cancer survival: a review

  2013cited by this paper
• Cancer prevalence estimates in Europe at the beginning of 2000.

  2013cited by this paper
• Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction?

  2013cited by this paper
• Clinical Management of Suppurative Osteomyelitis, Bisphosphonate-Related Osteonecrosis, and Osteoradionecrosis: Report of Three Cases and Review of the Literature

  2013cited by this paper
• Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).

  2013cited by this paper
• Safety and tolerability of adjuvant dose dense chemotherapy in elderly patients with node-positive early breast cancer.

  2013cited by this paper
• Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC).

  2013cited by this paper
• Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!

  2013cited by this paper
• Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature

  2013cited by this paper
• Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

  2013cited by this paper
• Prophylactic Use of Levonorgestrel-Releasing Intrauterine System in Women With Breast Cancer Treated With Tamoxifen: A Randomized Controlled Trial

  2013cited by this paper
• Abstract P2-15-02: Trastuzumab treatment of early breast cancer: Long-term results from a prospective observation study, including a large cohort of elderly patients

  2013cited by this paper
• Alcohol, DNA Methylation, and Cancer

  2013cited by this paper
• Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside.

  2013cited by this paper
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

  2012cited by this paper
• Abstract P6-12-01: Adjuvant treatment in breast cancer patients aged 70 years or older during three years. A systematic review of patients charts.

  2012cited by this paper
• Abstract P6-09-07: Impact of comprehensive geriatric assessment on treatment decision and follow-up in older breast cancer patients

  2012cited by this paper
• Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer

  2012cited by this paper
• Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score

  2012cited by this paper
• Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

  2012cited by this paper
• Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

  2012cited by this paper
• Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling

  2012cited by this paper
• Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy.

  2012cited by this paper
• Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study

  2012cited by this paper
• The eight-item modified Medical Outcomes Study Social Support Survey: psychometric evaluation showed excellent performance.

  2012cited by this paper
• Abstract P1-15-01: Patterns of granulocyte colony stimulating factor (G-CSF) use in elderly breast cancer (BC) patients receiving myelosuppressive chemotherapy:

  2012cited by this paper
• Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

  2012cited by this paper
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

  2012influential reference
• Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series.

  2012cited by this paper
• A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up.

  2012cited by this paper
• The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer.

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma

  2012cited by this paper
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

  2012cited by this paper
• Safety of adjuvant trastuzumab (T) in elderly patients with breast cancer.

  2011cited by this paper
• Cardiovascular effects of systemic cancer treatment.

  2011cited by this paper
• A population-based assessment of the risk of fragility fracture associated with the use of adjuvant hormone therapy for early breast cancer in older women.

  2011cited by this paper
• Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.

  2011cited by this paper
• Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

  2011cited by this paper
• Causes of death and relative survival of older women after a breast cancer diagnosis.

  2011cited by this paper
• Comparison of two frailty screening tools in older women with early breast cancer.

  2011cited by this paper
• Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.

  2011cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011cited by this paper
• Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• A randomized controlled trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with breast carcinoma of high estrogen receptor content: Long-term results at 20 years of follow-up.

  2011cited by this paper
• Reply to M.C. Chamberlain

  2011cited by this paper
• Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

  2011cited by this paper
• Comprehensive geriatric assessment for older adults admitted to hospital.

  2011cited by this paper
• Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 Patients

  2011cited by this paper
• Breast cancer racial disparities: unanswered questions.

  2011cited by this paper
• Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

  2010cited by this paper
• Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

  2010cited by this paper
• Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines.

  2010cited by this paper
• Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

  2010cited by this paper
• Mammographic screening for breast cancer: An invited review of the benefits and costs.

  2010cited by this paper
• Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines.

  2010cited by this paper
• Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use.

  2010cited by this paper
• Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

  2010cited by this paper
• EORTC elderly task force position paper: approach to the older cancer patient.

  2010cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

  2010cited by this paper
• Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience.

  2010cited by this paper
• American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• Comprehensive geriatric assessment in elderly breast cancer patients

  2010cited by this paper
• Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

  2009cited by this paper
• Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

  2009cited by this paper
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

  2009cited by this paper
• Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

  2009cited by this paper
• Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.

  2009cited by this paper
• Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

  2009cited by this paper
• Adjuvant chemotherapy in older women with early-stage breast cancer.

  2009cited by this paper
• High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

  2009cited by this paper
• Medication compliance and persistence: terminology and definitions.

  2008cited by this paper
• Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

  2008cited by this paper
• Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.

  2008cited by this paper
• Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

  2008cited by this paper
• Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.

  2008cited by this paper
• Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

  2008cited by this paper
• Early breast cancer in the elderly: assessment and management considerations.

  2008cited by this paper
• Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

  2008cited by this paper

• Neoadjuvant chemotherapy reduces the levels of HMGB1 and E-cadherin in patients with breast cancer

  2023cites this paper
• What are the clinicopathological features of elderly early-stage breast cancer patients and is there any difference in patients over 70 years of age?

  2019cites this paper
• Arm B : monotherapy pazopanib 800 mg ( 13 pts ) Arm C : monotherapy lapatinib 1 , 500 mg ( 36 pts ) breast cancer

  2017cites this paper
• Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta‐analysis

  2017cites this paper
• Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments

  2016cites this paper
• Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis.

  2016cites this paper
• Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis

  2016cites this paper
• Health economics of breast cancer management: An oversight

  2015cites this paper